Overview

Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions

Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, efficacy and tolerability of topical R333 ointment in Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) patients with active discoid lesions.
Phase:
Phase 2
Details
Lead Sponsor:
Rigel Pharmaceuticals